Noopept...experiences from a long term user

[John Juan]

[The original novel nootropic and neuroprotective agent noopept].

AuthorsOstrovskaia RU, et al. Show all Journal
Eksp Klin Farmakol. 2002 Sep-Oct;65(5):66-72. Article in Russian.

Affiliation
Abstract
The paper describes pharmacological properties of the new nootropic drug noopept created using an original approach based on the imitation of a nonpeptide nootrope structure by means of the short-peptide design. In particular, the structure of pyracetam was designed using dipeptide nootropes. Experimental investigations of noopept (N-phenylacetyl-L-polyglycine ethyl ester) showed that the new drug exceeds pyracetam both with respect to the effective dose level (1000 times lower for noopept than for pyracetam) and in the spectrum of mnemotropic activity. In contrast to pyracetam facilitating only the early stages of the memory process, noopept positively influences the memory consolidation and retrieval steps as well. The new drug produces an additional selective anxiolytic action. The pronounced neuroprotective effect of noopept was demonstrated both in vivo (in cases of various forms of brain ischemia) and in vitro (on various neuronal models). The drug action is based on the antioxidant effect, the antiinflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate, and to improve the blood rheology. It was established for the first time that the activity of noopept is retained both upon parenteral introduction and upon peroral administration, which is a principal advantage of this proline-containing dipeptide over other, more complex peptides. This property provided a basis for the development of a medicinal form of noopept for peroral usage. At present, noopept tablets (noopept 5 and 10 mg) are under clinical assessment as a means of treating cognitive deficiency of cerebrovascular and post-traumatic origin.

 

[FitnessSeattle]

I have found, with extensive observation, that the so called short term memory issues that some folks have reported are actually ' trances or profound reveries, we get so fixated on internal content that we forget what we were were doing.

 

[John Juan]

I like the fact that noopept increases intellectual ability while reducing sleep disorders. Stimulant based drugs only fulfill half the equation there. Good luck sleeping well on modafinil.

 

[John Juan]

Noopept increases cognitive ability making test taking much easier in college.

 

[John Juan]

Noopept dose falls between 10 mg and 40 mg taken up to three times a day. You it to kick in. Because Noopept increases alertness and blood flow to the brain, it is recommended that you do not use this compound late in the evening if you want a full night of sleep. Some reviewers recommend cycling their Noopept dosage schedule to improve its effectiveness, but this has not been proven necessary so far. In fact, because the effects of this nootropic is cumulative in its effects, taking it in consistent dosages over a long period of time may give you better results.

 

[John Juan]

Noopept’s effectiveness may be due to the possibility that it is able to strengthen associative connections between left and right brain hemispheres

 

[John Juan]

Noopept also has been shown in rodent studies to have neuroprotective properties important for brain plasticity.

 

[John Juan]

The administration of noopept favorably influences the cognitive functions and suppresses the development of neurodegenerative processes.

 

[John Juan]

Increased short term memory would be a great thing in my life.

 

[John Juan]

Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats).

AuthorsOstrovskaya RU, et al. Show all Journal
Bull Exp Biol Med. 2008 Jul;146(1):77-80.

Abstract

Experiments on adult Wistar rats showed that injection of beta-amyloid25-35 (2 microg) into Meynert basal nuclei caused long-term memory deficiency which was detected 24 days after this injection by the memory trace retrieval in conditioned passive avoidance reflex (CPAR). The effects of noopept, an original nootropic and neuroprotective dipeptide, on the severity of this cognitive deficiency were studied. Preventive (for 7 days before the injury) intraperitoneal injections of noopept in a dose of 0.5 mg/kg completely prevented mnestic disorders under conditions of this model. Noopept exhibited a significant normalizing effect, if the treatment was started 15 days after the injury, when neurodegenerative changes in the basal nuclei, cortex, and hippocampus were still acutely pronounced. The mechanisms of this effect of the drug are studied, including, in addition to the choline-positive effect, its multicomponent neuroprotective effect and stimulation of production of antibodies to beta-amyloid25-35. Noopept efficiency in many models of Alzheimer disease, its high bioavailability and low toxicity suggest this dipeptide for further studies as a potential agent for the treatment of this condition (initial and moderate phases).